BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 1362189)

  • 1. Long-term profile of a new progestin.
    Lippman J
    Int J Fertil; 1992; 37 Suppl 4():218-22. PubMed ID: 1362189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
    Teichmann A
    Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives.
    Quehenberger P; Loner U; Kapiotis S; Handler S; Schneider B; Huber J; Speiser W
    Thromb Haemost; 1996 Nov; 76(5):729-34. PubMed ID: 8950781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
    Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
    Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical evidence of the minimal androgenic activity of norgestimate.
    Chapdelaine A; Desmarais JL; Derman RJ
    Int J Fertil; 1989; 34(5):347-52. PubMed ID: 2571595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism.
    Godsland IF; Crook D; Simpson R; Proudler T; Felton C; Lees B; Anyaoku V; Devenport M; Wynn V
    N Engl J Med; 1990 Nov; 323(20):1375-81. PubMed ID: 2146499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical experience with a new norgestimate-containing oral contraceptive.
    Huber J
    Int J Fertil; 1992; 37 Suppl 1():47-53. PubMed ID: 1347520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Influence of progestins on adverse effects of oral contraceptives].
    Wynn V
    Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):425-30. PubMed ID: 12280210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical experience with a new norgestimate-containing oral contraceptive.
    Huber J
    Int J Fertil; 1991; 36 Suppl 1():25-31. PubMed ID: 1678378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Norgestimate: overview of a monophasic formulation.
    Anderson FD; Gillmer MD
    Int J Fertil Menopausal Stud; 1993; 38 Suppl 3():126-32. PubMed ID: 8260971
    [No Abstract]   [Full Text] [Related]  

  • 11. A norgestimate-containing oral contraceptive: review of clinical studies.
    Kafrissen ME
    Am J Obstet Gynecol; 1992 Oct; 167(4 Pt 2):1196-202. PubMed ID: 1415446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the impact of vaginal and oral administration of combined hormonal contraceptives on hepatic proteins sensitive to estrogen.
    Sitruk-Ware RL; Menard J; Rad M; Burggraaf J; de Kam ML; Tokay BA; Sivin I; Kluft C
    Contraception; 2007 Jun; 75(6):430-7. PubMed ID: 17519148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral contraceptives and blood coagulation.
    Bonnar J; Sabra AM
    J Reprod Med; 1986 Jun; 31(6 Suppl):551-6. PubMed ID: 2941571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus.
    Petersen KR
    Dan Med Bull; 2002 Feb; 49(1):43-60. PubMed ID: 11894723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of two oral contraceptives containing ethinyl estradiol and gestodene or norgestimate on different lipid and lipoprotein parameters.
    Wiegratz I; Jung-Hoffmann C; Gross W; Kuhl H
    Contraception; 1998 Aug; 58(2):83-91. PubMed ID: 9773262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a combined oral contraceptive pill in black Zimbabwean women.
    Kasule J; Mbizvo M; Makuyana D; Masona D
    Cent Afr J Med; 1991 Dec; 37(12):403-9. PubMed ID: 1806254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Potential advantages of triphasic combined oral contraceptives in the light of recent epidemiological and endocrinometabolic data].
    Gaspard U; Dubois M
    Contracept Fertil Sex (Paris); 1982 Sep; 10(9):551-60. PubMed ID: 12311606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative evaluation of the androgenicity of four low-dose, fixed-combination oral contraceptives.
    Coenen CM; Thomas CM; Borm GF; Rolland R
    Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():92-7. PubMed ID: 8574256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic effects of two low-dose triphasic oral contraceptives containing ethinyl estradiol and levonorgestrel or gestodene.
    Lepot MR; Gaspard UJ
    Int J Fertil; 1987; 32 Suppl():15-20. PubMed ID: 2906343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of desogestrel and gestodene in low-dose oral contraceptive combinations on lipid and lipoprotein status. A randomized prospective study.
    Granata A; Sobbrio GA; D'Arrigo F; Barillari M; Curasì MP; Egitto M; Trimarchi F; Granese D; Pullè C
    Acta Eur Fertil; 1990; 21(3):143-6. PubMed ID: 2149913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.